Clinical Trials on Verruca Vulgaris in Belgium

Total 21 results

University Hospital, Ghent

Completed

A Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares

Verrucae Vulgares

Belgium
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients (BIOLOPTIM-TIL)

Psoriasis Vulgaris

Belgium
University Hospital, Antwerp

Unknown

Studying the Skin Microbiome and the Potential of a Topical Probiotic Cream for Patients With Acne

Acne Vulgaris

Belgium
University Hospital, Ghent
University Ghent

Completed

Modified Intermittent Fasting in Psoriasis (MANGO)

Psoriasis | Psoriasis Vulgaris

Belgium
University Hospital, Ghent
Novartis

Completed

Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Vitiligo Vulgaris

Belgium
Galderma R&D

Completed

An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine

Acne Scars

Belgium
Stiefel, a GSK Company

Completed

An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne

Acne

Belgium, Netherlands
University Hospital, Ghent
Belgium Health Care Knowledge Centre

Not yet recruiting

Proactive TDM Versus Standard Use of Biologics in Psoriasis (HELIOS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent

Recruiting

Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) (BIOLOPTIM-RIS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Recruiting

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (BIOLOPTIM-BRO)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (BIOLOPTIM-GUS)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients (BIOLOPTIM-IXE)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Completed

Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. (BIOLOPTIM-SEC)

Psoriasis Vulgaris

Belgium
University Hospital, Ghent
KU Leuven; University Ghent

Terminated

Dose Tapering Study of Adalimumab in Psoriasis

Psoriasis Vulgaris

Belgium
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

Psoriasis Vulgaris

Belgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
Radboud University Medical Center
University Hospital, Ghent; ZonMw: The Netherlands Organisation for Health... and other collaborators

Active, not recruiting

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (BeNeBio)

Psoriasis | Psoriasis Vulgaris

Netherlands, Belgium
Galderma R&D

Completed

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Canada, Belgium, Germany, Italy
Galderma R&D

Completed

Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris (TEAM)

Acne Vulgaris

Australia, Belgium, Brazil, France, Germany, Italy, Mexico, Poland, Sweden
Bausch Health Americas, Inc.

Completed

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Acne Vulgaris

United States, Belgium, Canada
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands

Clinical Trials on Verruca Vulgaris in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations